Hosted on MSN

Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials

Cabaletta Bio Inc. (NASDAQ:CABA) is one of the best stocks under $3 to invest in. On October 27, Cabaletta Bio announced positive clinical data and development updates for its investigational targeted ...
Nasdaq

Cabaletta Bio Reports Promising Rese-cel Data In Autoimmune Diseases At Lymphocyte Conference

(RTTNews) - Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company, has reported promising clinical data for its investigational therapy, rese-cel or formerly CABA-201, in patients with ...
Yahoo Finance

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Business Wire

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...
FierceBiotech

Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...
Nasdaq

Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...